Sbir phase i topic 353: ctdna diagnostic enabled by magnetic automation assays

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201600036C
Awardee
Awarding agency
Obligated
$275,261

Award facts

Opportunity
  • PHS20161 Solicitation number
Contract value 100% obligated
$275,261.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 18 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Mountain View, CA 94040, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00002 $0
Other Administrative Action 1 $0
Original award $275,261

About this award

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nvigen, Inc., a small disadvantaged business and woman-owned manufacturer. The contract is for the development of cell-free tumor DNA (ctDNA) diagnostic enabled by magnetic automation assays, under SBIR Topic 353. The contract has a firm fixed price of $275,261.00 and a completion date of August 18, 2017. The contract does not utilize a set-aside designation.

Quick answers

Who was awarded contract HHSN261201600036C?

HHSN261201600036C was awarded to Nvigen, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.

How much is contract HHSN261201600036C worth?

The government has obligated $275,261 on HHSN261201600036C.

Was contract HHSN261201600036C competed?

The extent of competition for HHSN261201600036C was full and open competition. The government received 18 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award